Overweight Clinical Trials

62 studies are recruiting for overweight in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

San Antonio, Texas 21 Houston, Texas 19 Austin, Texas 16 Dallas, Texas 16 Miami, Florida 16 Chicago, Illinois 14 Jacksonville, Florida 14 Las Vegas, Nevada 14 Cincinnati, Ohio 13 Morehead City, North Carolina 12 Orlando, Florida 12 Birmingham, Alabama 11 Louisville, Kentucky 11 Tucson, Arizona 11 Walnut Creek, California 11 Atlanta, Georgia 10 Greensboro, North Carolina 10 Wilmington, North Carolina 10 Escondido, California 9 Los Angeles, California 9 Baltimore, Maryland 8 Honolulu, Hawaii 8 Indianapolis, Indiana 8 Nashville, Tennessee 8 New York, New York 8 Phoenix, Arizona 8 Skokie, Illinois 8 St Louis, Missouri 8 Columbus, Ohio 7 Fleming Island, Florida 7 Lawrenceville, Georgia 7 Monroe, North Carolina 7 Richmond, Virginia 7 Rochester, New York 7 Rolling Hills Estates, California 7 Southfield, Michigan 7 Tustin, California 7 Baton Rouge, Louisiana 6 City of Saint Peters, Missouri 6 Daytona Beach, Florida 6 DeSoto, Texas 6 Fargo, North Dakota 6 Greenville, South Carolina 6 Pittsburgh, Pennsylvania 6 Renton, Washington 6 San Diego, California 6 Springfield, Missouri 6 Sugar Land, Texas 6 Topeka, Kansas 6 Troy, Michigan 6 Waterbury, Connecticut 6 Weslaco, Texas 6 Weston, Florida 6 Chesterfield, Missouri 5 El Paso, Texas 5 Gulfport, Mississippi 5 Knoxville, Tennessee 5 Meridian, Idaho 5 Mesquite, Texas 5 New Port Richey, Florida 5

Studies now recruiting

  1. Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

    Background: In a previous study, participants were lived at the NIH and randomly received either a low-fat or a low-carbohydrate diet for 2 weeks and then switched to the other diet for 2 more weeks. Participants who received the low-carbohydrate diet first lost more body fat at the end of the stud…

    Stage
    Not phased
    Ages
    18 to 50
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT06325722 on ClinicalTrials.gov

  2. Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

    The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    Arizona Research Center, Phoenix, Arizona
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT07908316 on ClinicalTrials.gov

  3. Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

    Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how fat cells are metabolized.…

    Stage
    Phase 2
    Ages
    18 to 60
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    See if you can join NCT03407079 on ClinicalTrials.gov

  4. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

    Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Cahaba Research - Pelham /ID# 282381, Pelham, Alabama
    Locations
    64 in total
    Run by
    AbbVie

    See if you can join NCT07752979 on ClinicalTrials.gov

  5. Improving Glycemic Control With Electrical Stimulation

    Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels. Subjects will be provided with a standardized diet (55/15/30% CHO/PRO/FAT) prior to collection of pre-intervention data of insulin sensitivity. …

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas at El Paso, El Paso, Texas
    Run by
    University of Texas, El Paso

    See if you can join NCT03947697 on ClinicalTrials.gov

  6. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-2 Research Site, Birmingham, Alabama
    Locations
    74 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654374 on ClinicalTrials.gov

  7. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

    The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Diablo Clinical Research, Inc., Walnut Creek, California
    Locations
    13 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07607587 on ClinicalTrials.gov

  8. A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

    The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    PAREXEL Glendale/LA EPCU, Glendale, California
    Locations
    2 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07855133 on ClinicalTrials.gov

  9. A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

    The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    PAREXEL Glendale/LA EPCU, Glendale, California
    Locations
    2 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07868354 on ClinicalTrials.gov

  10. Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study

    The Active Older Adults prospective cohort study examines the effects of a park-based fitness program on cardiovascular fitness outcomes for older adults (aged 50 years and older). Duke will perform a secondary analysis of the data collected as part of the Active Older Adults prospective cohort stu…

    Stage
    Not phased
    Ages
    50 to 95
    Site
    Miami-Dade County Parks, Recreation and Open Spaces Department, Miami, Florida
    Run by
    Duke University

    See if you can join NCT06604650 on ClinicalTrials.gov

  11. A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

    The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Particip…

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    ICON Early Phase Services, LLC, San Antonio, Texas
    Locations
    3 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07654972 on ClinicalTrials.gov

  12. A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

    The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes. Participants will be in the study for about 11 months.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    16 in total
    Run by
    Pfizer

    See if you can join NCT07845500 on ClinicalTrials.gov

  13. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

    The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    San Fernando Valley Health Institute, Canoga Park, California
    Locations
    72 in total
    Run by
    Pfizer

    See if you can join NCT07595549 on ClinicalTrials.gov

  14. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Birmingham Clinical Research, Birmingham, Alabama
    Locations
    143 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07282600 on ClinicalTrials.gov

  15. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cullman Clinical Trials, Cullman, Alabama
    Locations
    115 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07369011 on ClinicalTrials.gov

  16. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona
    Locations
    40 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

  17. A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

    This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Pinnacle Research Group, LLC, Anniston, Alabama
    Locations
    180 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07794579 on ClinicalTrials.gov

  18. A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

    The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), …

    Stage
    Phase 1
    Ages
    18 to 60
    Site
    Fortrea Clinical Research Unit, Daytona Beach, Florida
    Locations
    2 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07808060 on ClinicalTrials.gov

  19. A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

    The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participa…

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    Fortrea Clinical Research Unit, Daytona Beach, Florida
    Locations
    3 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07808073 on ClinicalTrials.gov

  20. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona
    Locations
    57 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06143956 on ClinicalTrials.gov

  21. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    Stage
    Phase 3
    Ages
    6 to 17
    Site
    Lucas Research, Inc, Morehead City, North Carolina
    Locations
    116 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06672549 on ClinicalTrials.gov

  22. AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

    This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will ei…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Dignity Health, Mercy Gilbert, Gilbert, Arizona
    Locations
    92 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07571109 on ClinicalTrials.gov

  23. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Gilbert Center for Family Medicine, Gilbert, Arizona
    Locations
    45 in total
    Run by
    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

  24. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Pinnacle Research Group LLC, Anniston, Alabama
    Locations
    92 in total
    Run by
    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

  25. Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

    evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.

    Stage
    Not phased
    Ages
    21 to 65
    Site
    Cedars Sinai Medical Center, Los Angeles, California
    Locations
    5 in total
    Run by
    Nitinotes Surgical Ltd.

    See if you can join NCT07090005 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.